|
WO2021080529A1
|
|
Solid pharmaceutical formulations comprising ticagrelor
|
|
WO2021076066A1
|
|
Oral formulations comprising sitagliptin hci monohydrate with improved pharmaceutical characteristics
|
|
WO2021071444A1
|
|
A unique granulation process for rivaroxaban containing granules
|
|
WO2020101586A1
|
|
Controlled release propiverine formulations
|
|
WO2020101584A1
|
|
Sustained release acemetacin compositions
|
|
EP3796915A1
|
|
Oral formulations comprising rivaroxaban
|
|
EP3797098A1
|
|
Solid oral pharmaceutical compositions comprising phenyramidol or salts thereof
|
|
WO2019199246A1
|
|
A sustained release formulation comprising acemetacin with bimodal in vitro release
|
|
EP3474825A1
|
|
Sustained release formulation comprising tizanidine
|
|
EP3331502A1
|
|
Controlled release propiverine formulations
|
|
EP3294269A1
|
|
Oral pharmaceutical composition comprising otilonium bromide and simethicone with certain bulk density and improved dissolution characteristics
|
|
EP2965746A1
|
|
An oral pharmaceutical composition comprising ibuprofen, ibuprofen sodium dihydrate, pseudoephedrine hydrochloride and chlorpheniramine maleate
|
|
EP2978407A1
|
|
Aqueous solution composition containing ipratropium and oxymetazoline
|
